Vectorized was founded on the premise that the existing tools were too complex and not designed for today’s streaming requirements. Today the company released its first product, ...

VectorY is using an AAV5 variant to target the roughly 500,000 motor neurons in humans, a small slice of the 100 billion or so total neurons. The vectorized antibody treatment is administered into ...

Vectorized Inc., a new data management startup, today disclosed that it has raised $15.5 million across two funding rounds from Lightspeed Venture Partners and Alphabet Inc.’s GV fund. The ...

Title: ETX201: An experimental vectorized miRNA-based approach for the treatment of Angelman syndrome Presenter: Sirika Pillay, Ph.D., Director of Molecular and Cellular Pharmacology, Encoded ...

AMSTERDAM--(BUSINESS WIRE)--VectorY, a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, today ...